Disclosure under regulation 29(2) of SEBI(SAST) Regulations, 2011 received from Ishita Pharmaceuticals, related party of Ishita Drugs and Industries Limited
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Ishita Pharmaceuticals, a promoter group entity and related party of Ishita Drugs & Industries Ltd, acquired 250 equity shares (face value Rs. 10 each) of the company through the open market on February 12, 2026. This pushed its holding from 30,550 shares to 30,800 shares, representing about 1.03% of the company's total equity share capital (Rs. 2.99 crore across 29,90,300 shares). The acquisition is a marginal 0.01% increase and was disclosed under SEBI takeover regulations. The disclosure was signed by Sumit Jagdishprasad Agrawal as Partner of Ishita Pharmaceuticals and counter-signed by Abha Agrawal, Director of Ishita Drugs & Industries Ltd.
This is a very small, routine purchase by a promoter-group entity and is unlikely to have any material impact on the stock price or shareholder value. It signals continued promoter confidence but the tiny size makes it a non-event for investors.